A detailed history of Bokf, Na transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Bokf, Na holds 4,008 shares of NBIX stock, worth $503,044. This represents 0.01% of its overall portfolio holdings.

Number of Shares
4,008
Previous 4,031 0.57%
Holding current value
$503,044
Previous $555,000 0.72%
% of portfolio
0.01%
Previous 0.01%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 07, 2024

SELL
$130.86 - $143.19 $3,009 - $3,293
-23 Reduced 0.57%
4,008 $551,000
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $3,260 - $3,593
25 Added 0.62%
4,031 $555,000
Q4 2023

Feb 14, 2024

BUY
$106.07 - $132.76 $2,863 - $3,584
27 Added 0.68%
4,006 $527,000
Q3 2023

Nov 14, 2023

SELL
$94.02 - $117.1 $43,155 - $53,748
-459 Reduced 10.34%
3,979 $447,000
Q2 2023

Aug 21, 2023

SELL
$89.53 - $104.87 $22,561 - $26,427
-252 Reduced 5.37%
4,438 $418,000
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $34,538 - $45,148
-367 Reduced 7.26%
4,690 $474,000
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $28,174 - $33,543
264 Added 5.51%
5,057 $604,000
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $6,994 - $8,193
-76 Reduced 1.56%
4,793 $509,000
Q2 2022

Aug 11, 2022

BUY
$75.79 - $100.07 $5,381 - $7,104
71 Added 1.48%
4,869 $475,000
Q1 2022

May 13, 2022

BUY
$72.45 - $94.81 $11,374 - $14,885
157 Added 3.38%
4,798 $450,000
Q4 2021

Mar 11, 2022

SELL
$79.65 - $106.22 $67,782 - $90,393
-851 Reduced 15.5%
4,641 $395,000
Q3 2021

Nov 10, 2021

SELL
$86.18 - $99.03 $1.27 Million - $1.46 Million
-14,716 Reduced 72.82%
5,492 $527,000
Q1 2021

Apr 21, 2021

BUY
$87.57 - $119.4 $115,767 - $157,846
1,322 Added 7.0%
20,208 $1.97 Million
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $90,473 - $112,771
-1,041 Reduced 5.22%
18,886 $1.81 Million
Q3 2020

Oct 30, 2020

BUY
$96.16 - $135.15 $94,044 - $132,176
978 Added 5.16%
19,927 $1.92 Million
Q2 2020

Aug 12, 2020

SELL
$85.09 - $130.36 $84,579 - $129,577
-994 Reduced 4.98%
18,949 $2.31 Million
Q1 2020

May 13, 2020

BUY
$75.11 - $113.76 $211,885 - $320,916
2,821 Added 16.48%
19,943 $1.73 Million
Q4 2019

Feb 12, 2020

SELL
$86.8 - $118.57 $55,204 - $75,410
-636 Reduced 3.58%
17,122 $1.84 Million
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $20,452 - $24,766
-244 Reduced 1.36%
17,758 $1.6 Million
Q2 2019

Aug 14, 2019

BUY
$72.24 - $91.27 $899,749 - $1.14 Million
12,455 Added 224.54%
18,002 $1.52 Million
Q1 2019

May 15, 2019

SELL
$69.31 - $91.53 $700,862 - $925,551
-10,112 Reduced 64.58%
5,547 $489,000
Q4 2018

Feb 13, 2019

BUY
$68.32 - $124.36 $301,291 - $548,427
4,410 Added 39.2%
15,659 $1.12 Million
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $454,946 - $579,035
4,601 Added 69.21%
11,249 $1.38 Million
Q2 2018

Aug 13, 2018

BUY
$75.3 - $105.99 $500,594 - $704,621
6,648 New
6,648 $653,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Bokf, Na Portfolio

Follow Bokf, Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

News

Stay updated on Bokf, Na with notifications on news.